Zomedica Pharmaceuticals Corp (ZOM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zomedica Pharmaceuticals Corp (ZOM) has a cash flow conversion efficiency ratio of -0.050x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.65 Million) by net assets ($132.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zomedica Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Zomedica Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ZOM current and long-term liabilities for a breakdown of total debt and financial obligations.
Zomedica Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zomedica Pharmaceuticals Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INTER RAO Lietuva AB
WAR:IRL
|
0.213x |
|
Pansari Developers Limited
NSE:PANSARI
|
0.146x |
|
SK Innovation Co Ltd Pref
KO:096775
|
0.056x |
|
Defiance Silver Corp
V:DEF
|
-0.010x |
|
A-Tech Solution Co. Ltd
KQ:071670
|
-0.090x |
|
R K Swamy Limited
NSE:RKSWAMY
|
N/A |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
-0.001x |
|
Hotelim Société Anonyme
PA:MLHOT
|
N/A |
Annual Cash Flow Conversion Efficiency for Zomedica Pharmaceuticals Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Zomedica Pharmaceuticals Corp from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Zomedica Pharmaceuticals Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $195.66 Million | $-23.63 Million | -0.121x | -81.45% |
| 2023-12-31 | $240.02 Million | $-15.97 Million | -0.067x | -52.50% |
| 2022-12-31 | $267.39 Million | $-11.67 Million | -0.044x | +17.18% |
| 2021-12-31 | $270.89 Million | $-14.28 Million | -0.053x | +83.43% |
| 2020-12-31 | $51.07 Million | $-16.24 Million | -0.318x | +95.74% |
| 2019-12-31 | $2.10 Million | $-15.63 Million | -7.461x | -144.76% |
| 2018-12-31 | $3.66 Million | $-11.15 Million | -3.048x | -88.54% |
| 2017-12-31 | $4.39 Million | $-7.09 Million | -1.617x | -46.52% |
| 2016-12-31 | $4.13 Million | $-4.56 Million | -1.103x | -8115.62% |
| 2015-12-31 | $3.71 Million | $-49.88K | -0.013x | +95.42% |
| 2014-12-31 | $141.41K | $-41.44K | -0.293x | +2.74% |
| 2013-12-31 | $206.38K | $-62.19K | -0.301x | -- |
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more